EVMN5:43 PMEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic DermatitisTrial Results • Phase 2Top-line results Tue, Sep 8, 2026evommune.com
EVMN4:05 PMEvommune Reports Second Quarter 2026 Financial Results and Provides Business Highlightsevommune.com
EVMN8:00 AMEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine ProphylaxisTrial Start • Phase 2Trial initiation Thu, Jul 30, 2026, 8:00 AM EDTGevommune.com
EVMN8:30 AMEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous UrticariaTrial Results • Phase 2Top-line results Mon, Jun 29, 2026, 8:30 AM EDTGevommune.com